New Accenture service aims to enhance drug development and discovery
By Mia Burns
The global management consulting, technology services, and outsourcing company Accenture has launched a business service called Accenture Accelerated R&D Services that will focus on delivering streamlined and integrated R&D functions to help pharma companies bring new medicines to patients through a more collaborative and efficient approach. Accenture is investing more than $200 million in this new business venture.
Accenture Accelerated R&D Services will leverage capabilities of cloud, mobility, and analytics to deliver integrated functions across clinical development, regulatory submissions, pharmacovigilance, and market launch predicated on delivering better patient outcomes. The business service assists life science companies in getting drugs to market faster, at less cost, and with reduced execution risks using a pay-for-performance business model for business process outsourcing. The clinical services will focus on the traditional “pain points” of effectively identifying the right patients, helping efficient capture of clinical trial data and streamlining the process between data capture and reporting by leveraging the latest Clinical Data Interchange Standards Consortium, or CDISC criteria.
Last September, Accenture completed its acquisition of Octagon Research Solutions, Inc. David Boath, senior managing director of Accenture Life Sciences R&D practice told R&D Business Pharma Connect that the Accenture Accelerated R&D Services CDISC Conversion service feedback has exceeded expectations. “Octagon was a leader in that field,” he says. “They created a lot of the standards. They worked with the FDA to train people. They trained the FDA in those standards. They trained a lot of pharmaceutical companies in those standards. And then as companies had work to do, they would use Octagon to translate or move their current data into these new standards.”
Regarding the challenges in finding the patients best suited for clinical studies, Boath says, “When you design a study; you select a number of investigators to go and find those patients for you. When they do that, they make a commitment that they are going to find a number of patients. But actually at the end of the trial, you will see that half of those investigators that you thought were going to get patients for you actually don’t get a single patient. You have wasted a lot of time recruiting and training the investigator.”
Accenture has worked with Pfizer to build a first-of-its kind clinical data aggregation and exchange platform called Accenture Life Sciences Cloud, which is new to the industry. “We have been active in the market space because we have developed this solution with Pfizer and with Oracle, and the three of us are out there talking to other clients and encouraging them to join us,” Boath told R&D Business Pharma Connect.
According to Boath, Accenture has been working with CDISC since 2004, and the company has been involved with the companies within Transcelerate BioPharma for several decades. “We are now involved in managing several projects with them,” he says.
Posted: July 2013
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.